News

Biotech company Immunai has raised $215m in Series B funding round to accelerate the development of its immune-first drug actuary platform. Koch Disruptive Technologies led the funding round

Takeda Pharmaceutical has exercised its option to acquire GammaDelta Therapeutics to accelerate development of allogeneic γδT cell therapies to address solid tumours. In 2017, the companies formed a

Teva Pharmaceutical has partnered with Modag for the development and licensing of the latter’s drug candidates, anle138b and sery433, for neurodegenerative disease. Under the deal, Teva will have an

Vertex Pharmaceuticals has collaborated with Mammoth Biosciences to develop in vivo gene-editing therapies for two genetic diseases. As part of the partnership, the companies will use Mammoth’s next-generation

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has started a rolling review of molnupiravir (MK-4482 and EIDD-2801), an investigational oral antiviral medicine,

The European Commission (EC) has approved Merck’s Keytruda (pembrolizumab) plus chemotherapy combination to treat triple-negative breast cancer (TNBC) patients. Keytruda, an anti-programmed death receptor-1 (PD-1) therapy, blocks the

Clinical-stage biotechnology firm Atreca has signed a licensing agreement with the Bill & Melinda Gates Medical Research Institute (Gates MRI) for the development of a monoclonal antibody to

The Russia Ministry of Health has approved BeiGene’s Brukinsa (zanubrutinib) to treat patients with relapsed or refractory mantle cell lymphoma (MCL). Brukinsa is Bruton’s tyrosine kinase (BTK) molecule

Amgen has completed its previously announced acquisition of a clinical-stage biotechnology firm, Teneobio in a deal worth up to $2.5bn. The deal was announced in July this year.